
Management Update

Friday, 16 October 2026





Disclaimer

The information in this presentation has not been independently verified. This presentation is strictly private & confidential and is meant solely for your information only. Nothing in this presentation is or shall be considered to be an offer for the solicitation, sale or subscription of any securities. This presentation may also contain forward-looking statements that involve known or unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements (collectively, the “**Results**”) of the company & its subsidiaries (the “**Group**”) to be materially different from any future Results. Forward-looking statements were made based on assumptions regarding the present and future business strategies of the Group and the political and economic environment in which the Group will operate in the future. You are cautioned not to place undue reliance on these forward-looking statements, which are based on current view of the management of the Group as of the date of this presentation. Nothing in this presentation should be construed as financial, investment, business, legal or tax advice and you should consult your own independent professional advisers.

Company Overview



① Who We Are

Specialty pharmaceutical company with expertise in drug delivery systems

- ✓ Listed on SGX Catalist in July 2015
- ✓ Developed novel drug delivery platform optimised for sublingual administration of small molecules (WaferiX) and biologics (WaferlogiX)

② Platform Technology

Multi-drug platform delivery technology, comprising patented matrix formulation and proprietary freeze-dry manufacturing process

- ✓ **Novel highly porous, amorphous, non-ionic solid dose wafer formulation**

③ Business Model

Platform technology is ideal for **drug repurposing of approved drugs for new indications and/or new dosage forms**

- ✓ Speed to market with lower development costs and risk

④ Business Strategy

2 business segments

- i) Pharmaceuticals
- ii) Consumer Business

2 Business Segments



iX Biopharma Ltd

Pharmaceuticals

- **Wafermine Asset**
- **~ 40 repurposed sublingual formulations, including hormones & peptides**

Consumer Business

- **Longevity nutraceuticals: NAD, GSH**



PHARMACEUTICALS

Pharmaceutical Pipeline



40+ pharmaceutical products under development – Some highlights:

Small Molecules

Wafermine (Ketamine) – Pain/Depression
Wafesil (Sildenafil) – Male Erectile Dysfunction
BnoX (Buprenorphine) – Pain/Opioid Use Disorder
iXB 323 (Testosterone) – Hormone Replacement Therapy
iXB 326 (Estradiol) – Hormone Replacement Therapy



Peptides

MetaboliX Plus (GLP1 /SGLT2) – Obesity/Diabetes
Semorelin – Growth hormone support
Oxytocin – Emotional wellbeing/ Social anxiety



Biologics


FeroniX (Interferon Alpha) – Respiratory viral prophylaxis/treatment
iXB 321 (Influenza Vaccine, H1N1) – Influenza A



Wafermine for Acute, Moderate-to-Severe Pain




Wafermine



The world's first sublingual racemic ketamine wafer

- Novel MOA for pain and depression
- Non-opioid analgesic
- Anti-depressant via NMDA antagonist and AMPA Receptor Agonist

- Developed under FDA 505b(2) for acute, moderate-to-severe pain
- DoD to provide ~US\$41M funding for P3 Studies & EUA
 - Strong validation of iX's WaferiX Sublingual Technology
 - Funding derisks P3 study program; no dilution to capital base
 - Retain all rights and product sponsorship



Phase 2b: Study Protocol Overview



Completed Phase 2b, a multiple-dose study of the efficacy and safety of Wafermine™ in participants experiencing acute post-operative bunionectomy or abdominoplasty pain

Study Overview:

- Randomised, double-blind, placebo-controlled trial. 125 subjects enrolled. Conducted in USA.
- Two pain models evaluated: soft-tissue (**abdominoplasty n=40**), bony tissue (**bunionectomy n=85**)
 - Bunionectomy cohorts: Wafermine 50mg vs Wafermine 75mg vs Placebo (1:1:1)
 - Abdominoplasty cohorts: Wafermine 25mg vs Wafermine 50mg vs Wafermine 75mg vs Placebo (1:1:1:1)

Primary endpoint:

- **Summed Pain Intensity Difference** from baseline over **12-hours (SPID12)**. Multiple doses administered over 12 hours.


Phase 2b Results: Efficacy Similar to Opioids




➤ 75mg group (combined bunionectomy and abdominoplasty):

- ✓ Effect size 0.65*
- ✓ P value <0.01

Highly efficacious in two acute, post-operative pain models



Wafermine™ has similar efficacy to potent opioid, sufentanil, in abdominoplasty



*Based on SPID 12 data published by Recro Pharma (Meloxicam) and AcelRx (Sufentanil) standardised to placebo response

* Represents pooled effect size across both surgical groups. Effect sizes for bunionectomy and abdominoplasty groups were 0.84 and 0.76, respectively

Phase 3 Program Mimics Successful Phase 2

Two pivotal Phase 3 studies: randomized, double-blind, placebo-controlled, multiple-dose studies of Wafermine™, each followed by an open-label extension, in participants experiencing moderate-to-severe acute pain

- Two pain models evaluated: orthopedic (bunionectomy) and soft-tissue (abdominoplasty)
 - **KET006 Study** – Bunionectomy: Wafermine 75mg vs Placebo
 - **KET007 Study** – Abdominoplasty: Wafermine 75mg vs Placebo

Planned design:

- Sample size: n~240 per study
- Wafermine vs placebo
- Same primary endpoint as Phase 2b KET010 study

Military Emergency Pathway Open



Wafermine reaches final regulatory step

Pending EUA submission for approval



The Problem with Pain¹

80M

Prescribed for
Acute Pain in US

40M

Patients on opioids for
moderate to severe pain

~85,000

Suffer annually from
opioid use disorder

Big Pharma is All In!



Wafermine is Ready²

Driven by the opioid crisis, chronic pain epidemic, and increasing regulatory support for non-opioid pain therapies, the non-opioid pain market is one of pharma's fastest-growing segments

Eli Lilly to buy SiteOne for \$1 billion with eye on non-opioid pain drug

May 28, 2025 12:27 AM GMT+8 · Updated May 28, 2025



Clinical stage: Phase 2-ready

AbbVie inks \$745M deal with Chinese biotech Haisco for two acute pain assets

By Will Maddox · Apr 13, 2026 9:48am

Clinical Stage: Early-Stage to Phase 1

Opioid Crisis Response The Non-Opioids Prevent Addiction in the Nation (NOPAIN) Act, effective 2025, removes reimbursement barriers to non-opioid therapies, accelerating shift away from opioids in post-operative pain management

FDA Tailwinds Journavx (Jan 2025): First non-opioid drug class approved in 20+ years opened the floodgates
Analyst peak sales estimates: \$2-4B by 2030-2032

Big Pharma M&A Lilly: 2 non-opioid acquisitions in 2 years.
Active dealmaking

Investor Surge 96-fold increase in non-opioid pain financing value between 2015–16 and 2023–H1 2025

Sources:

1. Institute for Clinical and Economic Review (ICER), *Suzetrigine for Acute Pain: Effectiveness and Value, Final Evidence Report*, February 2025; U.S. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, *Drug Overdose Deaths in the United States, 2023*; Lopez et al., *A Real-World Database Analysis of the Prevalence of Pain Medication Use in the United States*, PAIN Reports, January 2026; Vertex Pharmaceuticals, "Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain" Press Release, January 2025
2. Grand View Research 2025; Straits Research 2026; Alacrita Non-Opioid Chronic Pain Market Analysis 2025; Vertex Pharmaceuticals 2024



CONSUMER BUSINESS

via Expansion into the US Market

Current Business Segments



iX Biopharma Ltd

Pharmaceuticals

- **Wafermine Asset**
- **~ 40 repurposed sublingual formulations, including hormones & peptides**


Consumer Business

- **Longevity nutraceuticals: NAD, GSH**

Restructuring Consumer Business



- Restructure & transfer all consumer related businesses to a Newco: Ligo Pharma



US Compounding Pharmacy



Compounding Pharmacies custom-make medications for patients or hospitals when standard drugs do not work or are not available

503A

Traditional pharmacies

Patient-specific prescriptions; small-scale; state-regulated

503B

Outsourcing facilities

Bulk drug production for hospitals; FDA-regulated like manufacturers

US Compounding Market¹

\$6.9B **\$11.85B** **6.2%**

Market Size 2025

Projected 2034

CAGR

Sources:

1. Nova One Advisor, U.S. Compounding Pharmacies Market Size and Forecast, 2025–2034

Expansion into the compounding market is a **strategic accelerator** for revenue, data and market validation

01 Immediate Monetization:

Commercialize ~40 of our novel sublingual formulations under 503A/B, bypassing lengthy FDA pathways to generate early cash flow while capturing real-world efficacy data

02 Scalable Partnerships:

Leverage 503A/B collaborations with established pharmacies for rapid market penetration

03 Dual Engines: Revenue + Data

Commercialize high-margin therapies today while refining future pipeline products based on patient insights

04 Springboard into the world's largest healthcare market



SUMMARY

WaferiX Platform - Two Growth Engines



Patented & Proprietary Sublingual Wafer Platform

A freeze-dried oral wafer that dissolves under the tongue

- 1) Rapid onset of action
- 2) Higher bioavailability
- 3) Easy administration

- **High barrier to entry around the sublingual wafer platform**
- **Validated by the US Department of Defense**
Endorsement at the highest institutional level

GROWTH DRIVER 1

Pharmaceutical

- Wafermine - sublingual ketamine for acute pain, treatment-resistant depression and suicidal ideation
 - Development advanced to P3, derisked with DoD support & funding
 - Monetization pathway: Out-licensing or Trade Sale
Non-opioid pain market ~US\$1.4B, growth driven by regulatory shift away from opioids
-


GROWTH DRIVER 2

Consumer Business

~40 repurposed sublingual formulations sold via compounding pharmacy pathway

- Products in high growth & demand categories such as men's & women's health, weight loss management & longevity etc
 - Wholesale supply to 503A pharmacies, hospitals and clinics
 - No clinical-trial risk, instant monetization
-

Unlocking Value



- A succession of major corporate milestones is building market conviction in three value drivers;
 - 1) US DoD funding of Wafermine P3 program
 - 2) Expanding into the US, the largest healthcare market via 503B compounding pharmacy and
 - 3) WaferiX platform technology

Stellar Market Performance

